Alzamend Neuro, INC 8-K filings

Alzamend Neuro is facing delisting from the Nasdaq Capital Market after failing to regain compliance with the minimum market value of listed securities requirement, but will appeal the decision.

Alzamend Neuro has amended a warrant and its Series B convertible preferred stock terms to ensure they are classified as equity, avoiding potential accounting issues.

Alzamend Neuro has amended its Series B preferred stock designations and eliminated its Series A preferred stock, clarifying voting rights and correcting previous errors.

Alzamend Neuro entered into a securities purchase agreement for up to $6 million in convertible preferred stock and warrants, while also receiving a notice of non-compliance from Nasdaq due to its stock price falling below $1.00.